Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amakem's rock inhibitor rolling towards the market

This article was originally published in Scrip

Executive Summary

Belgian biotech company Amakem has begun a proof-of-concept study with its lead product, the rho kinase (ROCK) inhibitor AMA0076, in glaucoma and ocular hypertension, after raising €18 million last year in a series A financing. The product is designed to avoid the risk of systemic and local side-effects such as hyperaemia that have caused problems for other products in this class, and uses the company's Localized Drug Action platform.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018916

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel